The Magazine for Sleep Professionals
Sunday, July 26, 2026
sovaSage has been named one of the Top 10 Sleep Therapy Solution Providers for 2026 by Healthcare Business Outlook. This recognition underscores sovaSage’s role in transforming how sleep therapy is delivered, combining advanced analytics, behavioral science, and human-centered design to improve patient outcomes and operational efficiency across the care continuum. […]
Narcolepsy Network, a national non-profit organization for people living with narcolepsy and idiopathic hypersomnia (IH), is proud to announce the appointment of Desireé Gorbea-Finalet and Mike Heil to its Board of Directors. Both new members live with narcolepsy and will bring fresh perspectives and deep advocacy experience to the organization as it prepares to […]
NightWare, Inc. and Exit 156 Capital announced a strategic investment by Exit 156 in NightWare’s ongoing Series C financing. NightWare is the maker of the only FDA-cleared prescription digital therapeutic indicated for nightmare disorder in adults with post-traumatic stress disorder (PTSD). The partnership unites a Minneapolis-based growth-stage digital health company […]
Dreem Health, a leading virtual sleep clinic managed by Sunrise Group, has become the first sleep care service to join Amazon’s Health Benefits Connector. Amazon customers eligible for insurance-covered sleep services can discover and enroll in Dreem Health’s personalized care when browsing for healthcare services. More than 70 million Americans live with sleep […]
ProSomnus Sleep Technologies announced that the U.S. Food and Drug Administration (FDA) has granted Class II 510(k) clearance for its RPMO₂ OSA Device under the product codes DQA, LQZ, LRK, PLC, and OUG (FDA K252765). The RPMO2 OSA Device is the first theragnostic device for sleep medicine, incorporating both precision […]
Apnimed, Inc., announced that it has entered into a senior secured credit facility for up to $150 million with funds managed by HealthCare Royalty Partners (“HCRx”). The capital is expected to support commercial readiness activities and the planned U.S. launch of Apnimed’s lead product candidate, AD109, if approved by the […]
On March 25, United States District Court Judge Rebecca L. Pennell sentenced Dr. Eric Edward Haeger, age 57, of Brewster, Washington, to one year and a day in federal prison followed by a one-year term of supervised release after Haeger pleaded guilty to adulterating and misbranding medical devices with the […]
Eli Lilly and Company and Centessa Pharmaceuticals plc, a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, announced a definitive agreement for Lilly to acquire Centessa. Centessa is advancing a pipeline of orexin receptor 2 (OX2R) agonists designed to […]
LivaNova PLC announced the U.S. Food and Drug Administration (FDA) granted premarket approval (PMA) for the aura6000™ System for the treatment of adult patients with moderate to severe Obstructive Sleep Apnea (OSA). The System utilizes proximal hypoglossal nerve stimulation (p-HGNS), a differentiated neurostimulation modality, to treat OSA in patients with […]
Sunrise Group announced results from the SUNSAS clinical study, now published in The Lancet Regional Health – Europe, a leading international medical journal. Supported by the French Ministry of Health through the Forfait Innovation program, this study is the largest randomized controlled trial to date evaluating an at-home diagnostic pathway for obstructive […]
